Contribution of UDP-Glucuronosyltransferase 1A1 and 1A8 to Morphine-6-Glucuronidation and Its Kinetic Properties
- 10 January 2008
- journal article
- research article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Drug Metabolism and Disposition
- Vol. 36 (4), 688-694
- https://doi.org/10.1124/dmd.107.019281
Abstract
The metabolic conversion of morphine to morphine-6-glucuronide (M6G) seems to play a significant role in mediation of the clinical effect of morphine because of the superior analgesic effect of M6G. Therefore, it would be of great interest to clarify the specificity of morphine-6-glucuronidation by UDP glucuronosyltransferase (UGT) isozymes. We investigated the specificity of morphine-6-glucuronidation catalyzed by recombinant human UGT isozymes in microsomes from baculovirus-infected insect cells. The morphine glucuronidation activity of recombinant human UGT isozymes incubated with morphine and UDP-glucuronic acid was determined by high-performance liquid chromatography with a fluorescence detector. Not only UGT2B7, which is well known to catalyze morphine-6-glucuronidation, but also UGT1A1 and 1A8 effectively catalyzed morphine-6-glucuronidation at relatively low morphine concentrations (Km values were 67.9 and 68.1 μM and the Ksi values were 218.9 and 88.0 μM for UGT1A1 and 1A8, respectively. These kinetics are basically different from that of morphine-6-glucuronidation by UGT2B7, which suggested biphasic Michaelis-Menten kinetic behavior. Furthermore, to estimate the contribution of these UGT isozymes in M6G formation in vivo, the expression levels of UGT1A1 and 1A8 mRNA in human liver and intestine were determined by reverse transcription real-time polymerase chain reaction. The results strongly suggest that UGT1A1 and UGT1A8 are isozymes involved in morphine-6-glucuronidation in vivo, as is UGT2B7 in humans.Keywords
This publication has 25 references indexed in Scilit:
- Morphine‐6‐glucuronide: Actions and mechanismsMedicinal Research Reviews, 2005
- Morphine-6-GlucuronideClinical Pharmacokinetics, 2001
- Human UDP-Glucuronosyltransferases: Metabolism, Expression, and DiseaseAnnual Review of Pharmacology and Toxicology, 2000
- Analgesic responses to intrathecal morphine in relation to CSF concentrations of morphine-3,β-glucuronide and morphine-6,β-glucuronideLife Sciences, 1999
- Isolation and Characterization of a Human Orphan UDP-Glucuronosyltransferase, UGT2B11Biochemical and Biophysical Research Communications, 1998
- Morphine and morphine-6-glucuronide plasma concentrations and effect in cancer painJournal of Pain and Symptom Management, 1996
- Morphine-6-glucuronide concentrations and opioid-related side effects: a survey in cancer patientsPain, 1995
- cDNA Cloning and Expression of Two New Members of the Human Liver UDP-Glucuronosyltransferase 2B SubfamilyBiochemical and Biophysical Research Communications, 1993
- Morphine Pharmacokinetics and Metabolism in HumansClinical Pharmacokinetics, 1993
- Analysis of morphine and its 3‐ and 6‐glucuronides by high performance liquid chromatography with fluorimetric detection following solid phase extraction from neonatal plasmaBiomedical Chromatography, 1993